Our choice of S-maltoheptaose26 is based on preliminary finding of in vitro efficacy of the sulfated malto-oligosaccharide series in displacement of NE from the syndecan complex in BALF of COPD subjects, increasing up the series from maltose to maltoheptaose. Here, SDC1 is linked to chronic obstructive pulmonary disease.